As Spinraza’s sales level off, Biogen presses ahead with aducanumab plans

Although Biogen’s earnings report suggests sales of SMA therapy Spinraza have plateaued, the company signaled its continued optimism that FDA will approve another potential blockbuster, its Alzheimer’s disease treatment aducanumab.

Revenues from Spinraza nusinersen dipped sequentially to $543.2 million in 4Q19 from $547.1 million in 3Q19; the drug also missed a quarterly consensus estimate of $558.4 million. Spinraza’s sales amounted to $2.1 billion for the full year, Biogen Inc. (NASDAQ:BIIB) reported Thursday.


Read the full 711 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers